Timothy Scott

Timothy Scott is co-founder and CEO of TEGA Therapeutics, a glycobiology company focused on lysosomal storage disorder and recombinant heparan sulphates. He previously was the founder and President of Pharmatek Laboratories, a contract development, and manufacturing company (sold to Catalent Pharma Solutions in 2016). Prior to that, Mr. Scott was Senior Vice President at Active.com. He previously served on the board of Zacharon Pharmaceuticals, which was sold to Biomarin in 2014. He is a member of the boards of BIOCOM, a non-profit organization supporting the needs of bio/pharma companies in California, and CONNECT, a non-profit helping to create and scale innovation companies in San Diego. At UC San Diego, he serves on the Dean’s Advisory Council for the Division of Biological Sciences. Mr. Scott earned his B.A. in Biochemistry from the University of California, San Diego. He earned his J.D. from the University of San Diego and is a member of the California Bar.